Jankey DM 500 Tablet ER

Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner. The combination therapy is indicated for patients inadequately controlled on monotherapy or dual therapy and aims to improve glycemic control while minimizing the risk of hypoglycemia.

Jankey DM 500 Tablet ER should be administered as prescribed by a healthcare professional, with dosage adjustments based on individual response and renal function. Common adverse effects may include gastrointestinal disturbances, urinary tract infections, and hypoglycemia. Regular monitoring of blood glucose, renal function, and potential side effects is recommended to optimize therapeutic outcomes and ensure patient safety.